The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).
Howard S. Hochster
No relevant relationships to disclose
Paul J. Catalano
No relevant relationships to disclose
Edith P. Mitchell
No relevant relationships to disclose
Deirdre Jill Cohen
No relevant relationships to disclose
Peter J. O'Dwyer
Other Remuneration - Lilly
Al Bowen Benson
Consultant or Advisory Role - Lilly/ImClone